Company Intercept Pharmaceuticals, Inc.
Stocks
ICPT
US45845P1084
Biotechnology & Medical Research
Business description: Intercept Pharmaceuticals, Inc.
Number of employees: 341
Sales by Activity: Intercept Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) |
|---|---|---|---|---|
Novel Therapeutics to Treat Progressive Non-Viral Liver Diseases | 252M | 313M | 363M | 286M |
Geographical breakdown of sales: Intercept Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) |
|---|---|---|---|---|
United States (U.S.) | 187M | 234M | 261M | 286M |
Ex-U.S. | 62.13M | 78.72M | 103M | - |
Executive Committee: Intercept Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Vivek Devaraj
PSD | President | - | - |
Rocco Venezia
DFI | Director of Finance/CFO | 51 | 2023-10-31 |
Veruska di Sena
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-31 |
Sangeeta Sawhney
CTO | Chief Tech/Sci/R&D Officer | - | 2024-03-31 |
Richard Johnson
HRO | Human Resources Officer | - | 2016-12-31 |
Composition of the Board of Directors: Intercept Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Devaraj
CHM | Chairman | - | - |
Company details: Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
305 Madison Avenue
07960, Morristown
+(646) 747-1000
http://www.interceptpharma.com
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.87% | +4.57% | +70.82% | +119.22% | 55.19B | |
| +4.00% | +7.14% | +63.67% | +68.77% | 45.75B | |
| -0.44% | +0.39% | -11.51% | -15.06% | 22.98B | |
| +3.76% | +1.58% | -6.09% | +386.73% | 20.76B | |
| -0.26% | -1.09% | +27.55% | -18.57% | 16.26B | |
| +1.16% | +3.86% | +22.36% | -36.42% | 15.42B | |
| -1.33% | -3.34% | +18.12% | +157.70% | 13.05B | |
| +3.30% | +15.38% | +133.24% | +273.89% | 12.45B | |
| -5.63% | -5.49% | +21.79% | - | 12.37B | |
| Average | +0.83% | +3.15% | +37.77% | +117.03% | 23.8B | |
| Weighted average by Cap. | +1.76% | +2.66% | +43.82% | +109.05% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
